Angiotensin receptor blockade and neprilysin (NEP) inhibition together offer potential
benefits for the treatment of hypertension and heart failure. LCZ696 is a novel single …

Abstract This 8-week, multi-center, open-label study assessed the safety and efficacy of
LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Japanese patients with …

LCZ696 (Japanese adopted name: sucabitril valsartan sodium hydrate), a first-in-class
angiotensin receptor neprilysin inhibitor, concomitantly inhibits neprilysin and blocks …

Neprilysin is an enzyme that contributes to the breakdown of the biologically active
natriuretic peptides and several other vasoactive compounds. Inhibiting neprilysin has been …

Background LCZ696 is a first-in-class inhibitor of the angiotensin II receptor and neprilysin.
We aimed to establish whether the dual actions of LCZ696 lead to further lowering of blood …

Neprilysin is a neutral endopeptidase and its inhibition increases bioavailability of natriuretic
peptides, bradykinin, and substance P, resulting in natriuretic, vasodilatatory, and anti …

Aims Concomitant renin–angiotensin–aldosterone system blockade and natriuretic peptide
system enhancement may provide unique therapeutic benefits to patients with heart failure …

The natriuretic peptide system exerts beneficial cardiorenal effects in chronic heart failure,
whereas activation of the renin–angiotensin–aldosterone system exerts opposing and …

Background Heart failure with preserved ejection fraction is associated with substantial
morbidity and mortality, but effective treatments are lacking. We assessed the efficacy and …

Background Increases in serum creatinine with renin–angiotensin–aldosterone system
(RAAS) inhibitors can lead to unnecessary discontinuation of these agents. The dual‐acting …